MelloMonday, 27th January 2025, 4.30pm - 8pm
Programme
4.30pm Interview with Fund Manager, Katen Patel
5:00pm Company presentation from Helios Underwriting plc
5:40pm Company presentation from Solvonis Therapeutics (formerly Graft Polymer)
6.20pm Educational session
6:35pm Company presentation from Cohort plc
7:05pm BASH Panel featuring Kevin Taylor and Mark Simpson (Kooth KOO)
Interview with Katen Patel, Fund Manager, J.P. Morgan Asset Management International Equity Group
Katen Patel, executive director, is a portfolio manager within the J.P. Morgan Asset Management International Equity Group, based in London. An employee since April 2013, he previously worked at HSBC Bank Plc in a European equity sales role. He obtained a BSc. in Management from the London School of Economics and Political Science. Katen is a CFA charterholder.
Company presentation – Helios Underwriting PLC
Helios Underwriting PLC is an investment vehicle which builds shareholder value through participation in the Lloyd’s of London market.
Helios has curated a diversified and volatility-managed portfolio, comprised of capacity in some of the best performing syndicates at Lloyd’s.
It is a capital efficient business, providing investors with a return uncorrelated to equity markets.
Helios Website: https://www.huwplc.com/
Arthur Manners – Finance Director
Arthur has over 20 years’ experience in the insurance industry. He has worked at Helios since June 2015 and joined the Board in April 2016. His role as Finance Director at Helios is part time. Arthur previously worked for Beazley Group plc from 1993 to 2009 as Finance Director and latterly as Company Secretary. He remains Chairman of the Trustees of the Beazley Furlonge Pension Scheme.
Company presentation – Cohort plc
Cohort plc (www.cohortplc.com) is the parent company of six innovative, agile and responsive businesses based in the UK, Germany and Portugal, providing a wide range of services and products for domestic and export customers in defence and related markets.
Cohort (AIM: CHRT) was admitted to London’s Alternative Investment Market in March 2006. It has headquarters in Reading, Berkshire and employs in total over 1,300 core staff there and at its other operating company sites across the UK, Germany, and Portugal.
Andrew Thomis – CEO
Andrew graduated with an MEng degree in Electrical and Electronic Engineering from Imperial College London in 1987. He spent nine years in science, technology and policy roles in the UK MOD. He left in 1996 and, after a period working with public and private sector clients at Capita plc’s management consultancy arm, he joined Alvis in a role covering strategy, M&A and business development. Following the acquisition of Alvis by BAE Systems in 2004, Andrew worked with Nick Prest and Stanley Carter on the creation of Cohort plc, acting as Finance Director during the flotation and subsequently Corporate Development Director. From 2007 to 2009 he was Managing Director of MASS. Andrew is a Fellow of the Institution of Engineering and Technology.
Company presentation – Solvonis Therapeutics plc
Solvonis is innovative biotechnology company developing intellectual property related to the treatment of mental health disorders and substance use disorders, and co-developing therapeutics for mental health disorders, with an initial focus on Post-Traumatic Stress Disorder (PTSD).
PTSD affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the U.S., UK, and key EU markets.
Solvonis is in the process of acquiring CSE listed Awakn Life Sciences.
Awakn is A clinical-stage biotechnology company developing therapeutics for substance use disorders and mental health disorders. Awakn has a near-term focus on Alcohol Use Disorder (AUD).
AUD affects approximately 29 million adults in the US with Awakn estimating a current affected population of 40 million in the US and US and key European markets for which the current standard of care is inadequate.
Anthony Tennyson – CEO
Anthony is the CEO and co-founder of Solvonis Therapeutics. He is also a non-executive director at Empowerment Plus, an Irish non-profit supporting young people and families at risk.
Before moving into the healthcare sector, Anthony worked in financial services. He spent ten years in international strategy and commercial leadership roles at Aon Plc and worked at Merrill Lynch and Bank of Ireland for five years. Anthony holds an MBA and an MSc from University College Dublin (UCD).
The Mello BASH (Buy, Avoid, Sell & Hold)

Mark Simpson, Private Investor

Kevin Taylor, Private Investor